Thirty thalassaemia patients received iron reduction starting at around 3 months post transplant. Sixteen received desferrioxamine and nine had phlebotomy, five patients had desferrioxamine followed by phlebotomy. The desferrioxamine group had higher serum ferritin levels at the start of iron reduction as compared to the phlebotomy group (5292 vs 2453 g/l, P EQ 0.001). After 444 and 407 days of iron reduction, serum ferritins at cessation of iron reduction in both groups was similar (665 vs 588 g/l). The rate of decline of serum ferritin in both groups was similar. There was no graft rejection during the programme. Early institution of iron reduction in ex-thalassaemia is safe. Bone Marrow Transplantation (2000) 25, 653-656.
Iron overload is the leading cause of death in thalassaemia major patients. 1 Bone marrow transplant (BMT) is the only curative treatment, and 'ex-thalassaemia' patients do not require further transfusion. 2 However it has been shown that iron overload may persist for many years after transplant. 3 The Pesaro Centre has used either phlebotomy or desferrioxamine (DFO) for removal of excessive body iron, 4, 5 but the programme usually starts late after transplant. There are no guidelines on the optimal timing of initiating iron depletion. We report our experience of early iron reduction starting at around 3 months after transplant.
Materials and method
Thalassaemia major patients receiving BMT at the Prince of Wales Hospital, Hong Kong were potential candidates for the iron reduction programme. The details of transplant procedures have been reported previously. 6 Patients received cyclosporin at 3 mg/kg/day i.v. or 12 mg/kg/day p.o. for 50 days, and then tapered at 5% per week until day 180 if there was no acute or chronic GVHD. After engraftment and when free from early complications of transplantation, patients were started on iron reduction therapy. From December 1992 to March 1995, patients were treated with DFO 50 mg/kg daily either by intravenous infusion via a Hickman catheter or subcutaneous infusion over 10 to 12 h. From March 1995 onwards, patients were offered the options of phlebotomy or DFX. Phlebotomy was performed if the untransfused haemoglobin (Hb) was more than 10 g/dl. About 10 ml/kg of blood would be removed at 4 weekly intervals. There was no volume replacement during each phlebotomy. The phlebotomy was performed via a peripheral vein or from the Hickman catheter if it was still in situ. The target end point of iron reduction was a serum ferritin of 500 g/l. Complete blood counts, serum ferritin and liver enzymes were monitored serially. The continuous variables were expressed as the mean ± standard deviation (s.d.). Differences were tested for significance by Mann-Whitney test or Student's t-test.
Results
From August 1992 to December 1997, 39 thalassaemia major patients received allogeneic stem cell transplants. Thirty patients were recruited for the iron reduction programme. The mean age at transplant was 10.9 ± 5.3 years (range 2.6-21.1). Twenty-one patients received DFO treatment but five subsequently switched to phlebotomy. Fourteen patients were treated by phlebotomy, and nine had phlebotomy as the only iron reduction method. Patient characteristics are shown in Table 1 . Chronic hepatitis was not evident in any of these patients. The mean serum ferritin at time of BMT was 2005 ± 1534 g/l, but increased to 4256 ± 2877 g/l before iron reduction. Liver enzyme (ALT) was mildly elevated in five patients at time of BMT, but was elevated in 20 patients at time of starting iron reduction, 125 ± 148 IU/l. None of the patients had hepatitis B surface antigen or antibody to hepatitis C virus. No patient developed chronic GVHD during the study period and all had cyclosporin stopped according to schedule at 6 months post transplant. Twenty-one patients were treated with DFO after BMT. The median day of starting DFO was 88 days, ranging from 33 to 206 days. The serum ferritin at start of iron reduction was 5292 ± 3116 g/l (range 1970-12989). The DFO dosage was 45 ± 2 mg/kg (30-60 mg/kg). One patient had hearing impairment on day 160, at 3 months after DFO treatment, but this resolved after reducing the DFO dosage to 25 mg/kg. One patient developed a generalised convulsion on day 146 while on DFO treatment. No causes could be found for this, cyclosporin having already been tapered to a low dose, 3 mg/kg/day. DFO was stopped and the patient was then switched to phlebotomy. The other patients did not develop toxicity from DFO such as visual impairment. Four other patients switched to phlebotomy because of poor compliance with DFO treatment. The duration of DFO treatment was 391 ± 274 days for all 21 patients, and 444 ± 263 days for the 16 patients who received DFO only. The rate of fall in serum ferritin was 405 ± 301 g/l per month, or 13 ± 12% per month. The serum ferritin at time of stopping DFO was 665 ± 733 g/l.
Fourteen patients were started on the phlebotomy programme at a median of 121 days (range 53-733) after BMT. For the nine patients who received phlebotomy as initial treatment, the starting day was 103 ± 25 days (range 53-146). The Hb level at start was 11.6 ± 1.0 g/dl, which was significantly higher than that of the DFO group (P Ͻ 0.001). A total of 197 phlebotomies was performed over 407 ± 261 days. The mean number of phlebotomies was 14 ± 9.2 (range 5-39). There were no complications post phlebotomy, and all the patients adhered to the programme. The Hb level did not fall below 10 g/dl at the scheduled 4 weekly intervals. The serum ferritin at start of iron reduction was 2453 ± 1232 g/l, which was significantly lower than that of the DFO group (P = 0.001). The rate of fall of serum ferritin was 155 ± 82 g/l per month which was also significantly slower than the DFO group (P = 0.001). However, the serum ferritin at the end of programme and the percentage of decline in serum ferritin per month did not differ from that of the DFO group (Table 2) .
Liver enzymes improved and ALT levels dropped significantly at the end of iron depletion in both groups. During the DFO and phlebotomy programmes, there was no suppression of WBC and platelet counts in either group. Assessment of chimerism status was successful in 27 patients by either FISH or DNA VNTR methods. Twentyone patients had complete donor chimerism which remained during iron reduction. Six patients had mixed chimerism, and levels of recipient cells at time of starting iron reduction were from 5% to 77%. Three patients reverted to complete donor chimerism, two in the phlebotomy group and one in the DFO group, and mixed chimerism was at a low level of less than 15% recipient cells. Three patients maintained stable mixed chimeric status, two in the phlebotomy group and one in the DFO group, and they had higher levels of recipient cells 17-77%. No graft rejection occurred and all remained transfusion independent.
Discussion
BMT is the only curative treatment for transfusion-dependent thalassaemia. Iron overload persists into the post-transplant period for a variable duration. It has been shown that some patients still have iron overload for many years after BMT, especially those who were older and more heavily iron overloaded before transplant. 7 Iron depletion after BMT by DFO or phlebotomy has been shown to effectively deplete body iron. However, patients only started the iron depletion programme very late after BMT, usually more than 2 years from BMT. Iron overload is aggravated during the early post-transplant period due to additional red cell transfusion in the first 1-2 months, and there is also release of iron from bone marrow after conditioning. The incidence of iron-induced organ damage in thalassaemia patients correlates with the duration of exposure to high serum ferritin. 1 Busulphan and cyclophosphamide given during conditioning are also toxic to the liver and heart. 8 These patients may be particularly prone to iron-induced tissue damage in the early post-transplant period, and one of our patients developed diabetes mellitus 4 months after BMT. Early institution of iron depletion therapy may be beneficial to those heavily iron overloaded patients.
Early treatment with DFO or phlebotomy has been shown to be safe in our programme. The hearing and visual toxicity associated with DFO is reversible after discontinuation or dose reduction of DFO. DFO has been shown to have an anti-proliferative effect 9 and there is concern about marrow suppression in the early post-transplant phase. There is only one report of using DFO early after BMT and there was no adverse effect on engraftment. 10 In our series, none of the patients had significant drops in Hb or other blood counts during DFO treatment, even though some of them started as early as 1-2 months after BMT. We stopped the DFO treatment at a ferritin level of around 500 g/l instead of a normal value because there is higher chance of DFO toxicity when the body iron is not very high. This level of serum ferritin is also safe for thalassaemia patients. Phlebotomy stimulates the hyperplastic bone marrow after BMT, and the residual recipient cells may also be stimulated. Serial monitoring of our four patients with mixed chimerism receiving phlebotomy did not show graft rejection. Two of them even had their chimeric status revert to entirely donor cells, and the other two remained with stable mixed chimerism. There may also be stimulation of ineffective erythropoiesis and a consequent increase in iron absorption after repeated phlebotomies, which will have the opposite effect on iron reduction. In our series, the group receiving phlebotomy showed a satisfactory decline in ferritin and the possible increase of iron absorption would not have been significant if indeed there was any.
In our study, phlebotomy achieved a similar degree of iron reduction over a similar time period as compared to DFX. However, the DFO group had higher starting ferritin levels and thus the absolute decrease in ferritin per month was greater in the DFO group (405 vs 156 g/l). This is not surprising, as DFO has been demonstrated to remove 100 to 300 mg iron daily, whereas phlebotomy can only achieve a reduction of 0.5 mg/ml blood removed. In order 655 Table 2 Comparison of iron depletion groups to achieve more rapid iron removal, phlebotomy may be performed at more frequent intervals with close monitoring of the Hb level. Serum ferritin is an acute phase reactant; its value is limited by variables relating to factors other than iron status, such as hepatitis, infection, inflammatory disorders and malignancy. In the first year after transplant, patients may have a high serum ferritin due to other concurrent conditions and this may fall without intervention. All of our patients had further elevations of ferritin as compared to the pre-transplant values. Since we do not have a control group not receiving iron reducing therapy, the fall in serum ferritin in our patients may be over-estimated. However, the ferritin level on stopping the iron reduction programme was much lower than the pre-transplant values, 588 vs 2005 g/l at around 18 months post transplant. The very high serum ferritin only decreased to below pre-transplant values at least 3 years after BMT if patients did not receive any iron depleting intervention. 3 Iron overload in patients with high ferritins is supported by persistent hepatic haemosiderosis on liver biopsy. We believe that early iron reduction by DFO or phlebotomy achieved effective iron removal in our patients. Serial hepatic iron measurement by either superconducting quantum interference device (SQUID) susceptometer or liver biopsy provides more accurate measurement of body iron; 11 however, SQUID is only available in a few centres. Needle liver biopsy is commonly performed in thalassaemia, but it is still an invasive procedure with associated risk especially after repeated biopsy. 12 Phlebotomy has the advantage of better compliance, fewer side-effects and cost saving. We recommend phlebotomy for all post-transplant thalassaemia patients starting at about 3 months after transplant. DFO is given only to patients who do not achieve a high enough Hb level for phlebotomy. Potential toxicity from DFO should be monitored closely as these patients are not receiving further blood transfusion. In conclusion, early start of an iron reducing programme appears safe in thalassaemia patients. Phlebotomy is the preferred mode of iron reduction in most patients.
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